Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor
MT newswire2026/10/05 13:5809:58 AM EDT, 10/05/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Monday that it has received US Food and Drug Administration approval for technology that provides updates directly to patients through its CardioMEMS HF System. The company said the technology allows doctors to share daily heart pressure readings directly with patients between office visits. It said the technology also provides the ability to send medication adjustment instructions to patients' smartphones and measures pressure through an implanted sensor in the pulmonary artery. Abbott said it plans to make CardioGuide HF App and Dynamic Treatment Plan available later in the year. Price: 97.69, Change: +0.19, Percent Change: +0.19
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Altaris Completes Acquisition of Simulations Plus
02:57 PM EDT, 10/06/2026 (MT Newswires) -- Simulations Plus (SLP) said Tuesday that affiliates of Altaris have completed the acquisition of the company. The transaction price was $375 million, with each Simulations shareholder receiving $18.50 in cash per share, according to an earlier statement. As a result of the acquisition, Simulations said it has become a privately held company and its common stock will no longer trade on the Nasdaq Global Select Market.
Ondo Finance brings pre-IPO AI exposure on-chain — But there’s a catch
Philippines: One more BSP hike expected in October - Standard Chartered
The Reality of AI Agentic Payments in 2026
Crypto prices
More
